In patients with follicular lymphoma, delayed-onset neutropenia …
Dec 12, 2024 · The prevalence of anti-CD20 monoclonal antibody (MoAb)-associated delayed-onset neutropenia (DON) varies between 8 and 27%. Despite the wide use of MoAbs as maintenance in …
Administration of Obinutuzumab, and Not Rituximab, during Induction …
Nov 15, 2022 · Rituximab-associated delayed neutropenia, defined as an event occurring after recovery of cytopenias related to the chemotherapy backbone, has been reported in lymphoma patients, with …
Prolonged cytopenias after immune effector cell therapy and ...
Higher incidence of severe thrombocytopenia and neutropenia after immune effector therapy for leukemia compared with lymphoma or ST Severe thrombocytopenia was more commonly observed …
Follicular lymphoma - Canadian Cancer Society
Follicular lymphoma is a type of non-Hodgkin lymphoma (NHL). Treatments include watchful waiting, radiation therapy, targeted therapy, chemotherapy, immunotherapy and stem cell transplant.
Follicular Lymphoma Treatment Guidelines
Home » Resources » Healthcare Professionals » Treatment Guidelines » Follicular Lymphoma Treatment Guidelines Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma …
In patients with follicular lymphoma, delayed-onset neutropenia …
Dec 12, 2024 · The prevalence of anti-CD20 monoclonal antibody (MoAb)-associated delayed-onset neutropenia (DON) varies between 8 and 27%. Despite the wide use of MoAbs as maintenance in …
Novel immunotherapy approaches to follicular lymphoma - PMC
Follicular lymphoma (FL) remains a lymphoma subtype that is remarkably sensitive to immunotherapy-based treatment strategies. Anti-CD20 antibody therapy administered as a single agent and in …
The prevalence of anti-CD20 monoclonal antibody (MoAb)-associated delayed-onset neutropenia (DON) varies between 8 and 27%. Despite the wide use of MoAbs as maintenance in follicular lymphoma …
Relapsed/Refractory Follicular Lymphoma: Current Advances and …
Feb 19, 2025 · Follicular lymphoma (FL) is a prevalent indolent non-Hodgkin lymphoma (NHL) characterized by a relapsing course and eventual refractoriness to therapy. Despite advancements in …
Current state-of-the-art of immunotherapy in follicular lymphoma
Jun 19, 2025 · The advent of immunotherapy has rapidly changed the treatment landscape of follicular lymphoma (FL).Autologous CD19 chimeric antigen receptor T- cell (CAR-T) products show …